BCM
CRNX icon

Bourgeon Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Bourgeon Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-4,150
Closed -$66.6K – 339
2023
Q1 		$66.6K Buy
4,150
+1,500
+57% +$27.8K 0.02% 132
2022
Q4 		$48.5K Buy
+2,650
New +$46.7K 0.01% 155

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bourgeon Capital Management's CRNX Position: Q2 2023 in Review

Bourgeon Capital Management sold out of Crinetics Pharmaceuticals (CRNX) in Q2 2023, closing a stake of 4,150 shares — an estimated $66.6K sold.

Bourgeon Capital Management first reported a position in CRNX in Q4 2022 and held it in 2 quarters. The position peaked at $66.6K in Q1 2023. 140 funds tracked by Wall St. Rank hold CRNX as of Q2 2023.

  • Bourgeon Capital Management reported no remaining Crinetics Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Bourgeon Capital Management sold 4,150 Crinetics Pharmaceuticals shares in Q2 2023, an estimated $66.6K.
  • Bourgeon Capital Management first reported a position in Crinetics Pharmaceuticals in Q4 2022 and held it in 2 quarters.
  • Bourgeon Capital Management's Crinetics Pharmaceuticals position peaked at $66.6K in Q1 2023.
  • 140 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2023.

Based on Bourgeon Capital Management's 13F filing for Q2 2023, filed 20 Jul 2023.